These unique therapies treat well-defined medical conditions, replacing missing or deficient proteins found in plasma, to allow their recipients to lead healthier and more productive lives. The patient populations that rely upon plasma protein therapies generally require regular infusions or injections for the duration of their lives.
Plasma-derived therapies and their recombinant analogs, collectively referred to as plasma protein therapies, are unique, biologic medicines, versus synthetic or chemical medicines, because production begins with plasma, a biologic starting material. Each therapy has its own unique biochemical profile, due to differences in production and processing methods, which results in different clinical responses and efficacy among patients.
Plasma protein therapies are not interchangeable and have been defined by regulators as sole-source biologic products because no generics or substitutions exist. In addition, their biological nature demands storage and handling requirements by specialty distributors that ensure their safety.
Plasma protein therapies are unique, biologic medicines that are either infused or injected to treat a variety of rare, life-threatening, chronic and genetic diseases. Learn more about the therapies used to treat these diseases and the patients who rely on plasma protein therapies.
PPTA is Proud to Support Rare Disease Day 2017 +
The Plasma Protein Therapeutics Association (PPTA) is proud to support Rare Disease Day, an annual international event that seeks to raise awareness about rare diseases and the patients and families that are affected by a rare disease.Read More
PPTA Statement on the Documentary “Das Geschäft mit dem Blut” +
PPTA has viewed the documentary "Das Geschäft mit dem Blut" / "Le business du sang" (http://future.arte.tv/fr/le-business-du-sang) that will air on Feb. 21, 2017 in Germany, France, and Belgium on ARTE TV. PPTA strongly objects to the content of the documentary because it is not factual and contains numerous inaccuracies and misinformation.Read More
PPTA Remembers Corey Dubin +
The Plasma Protein Therapeutics Association (PPTA) notes with sadness the passing of Corey Dubin, President Emeritus of the Committee of Ten Thousand and longtime advocate in the hemophilia community.Read More
Chief Executive of the Irish Haemophilia Society on PPTs